Impact of MDM2 gene polymorphism on sarcoma risk

Area of Science:

• Genetics and Oncology
• Molecular Biology
• Cancer Epidemiology

Background:

• Conflicting findings exist regarding the association between the MDM2 gene single nucleotide polymorphism (SNP, rs2279744) and sarcoma risk.
• The MDM2 gene plays a crucial role in cell cycle regulation and tumor suppression.

Purpose of the Study:

• To clarify the relationship between MDM2 SNP rs2279744 and sarcoma risk through a comprehensive meta-analysis.
• To evaluate the association in specific populations, particularly Caucasians.

Main Methods:

• A systematic literature search was conducted across PubMed, Web of Science, and Science Direct databases.
• Human case-control studies with complete genetic data on MDM2 SNP rs2279744 and sarcoma risk were included.
• Pooled odds ratios (ORs) were calculated using fixed-effect or random-effects models.

Main Results:

• The overall analysis of five studies indicated that the T/G genotype or combined G/G and T/G genotypes were associated with a 1.40-fold higher risk of sarcoma compared to the T/T genotype.
• Caucasian populations showed a similar increased risk, with ORs of 1.41 for T/G and 1.49 for G/G + T/G genotypes versus T/T.
• The T/G genotype showed an OR of 1.33 (95% CI 1.00-1.77) and the G/G + T/G genotypes showed an OR of 1.42 (95% CI 1.08-1.85) for sarcoma risk.

Conclusions:

• MDM2 SNP rs2279744 is significantly associated with an increased risk of sarcoma.
• This association is particularly notable in Caucasian individuals carrying the T/G or G/G genotypes.